Premium
Etodolac, aspirin, and gastrointestinal microbleeding
Author(s) -
Arnold John D,
Mullane John F,
Hayden Dan M,
March Lillian,
Hart Kay,
Perdomo Carlos A,
Fencik Monica,
Berger Arthur E
Publication year - 1984
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.1984.100
Subject(s) - etodolac , aspirin , placebo , medicine , anesthesia , pharmacology , gastroenterology , pathology , alternative medicine
The effects of etodolac, a new nonsteroidal anti‐inflammatory drug, on gastrointestinal (GI) microbleeding were quantitatively assessed in two studies in healthy adult men. The first was a two‐group, open‐label, parallel comparison of etodolac, 600 mg/day, aspirin, 2600 mglday, and placebo in 20 subjects; the second was a four‐group, double‐blind, parallel comparison of etodolac, 600, 800, and 1200 mglday, aspirin, 2600 mg/day, and placebo in 41 subjects. Subjects in both studies received a single‐blind placebo on days 1 through 7, either etodolac or aspirin on days 8 through 14, and a single‐blind placebo on days 15 through 19. GI blood loss (milliliters per day) was estimated by the radiolabeled ( 51 Cr) erythrocyte method and was based on daily radioactivity counts of stool specimens and regression‐estimated daily blood radioactivity. Etodolac, 600 mglday, induced no significant GI blood loss at any time during the experiments, nor was there significant blood loss after 800 and 1200 mg/day in experiment 2. Blood loss was noted after aspirin in both. Clinical Pharmacology and Therapeutics (1984) 35, 716–721; doi: 10.1038/clpt.1984.100